ReviewFrontiers in pediatrics2026
Sarcopenic obesity and skeletal development in children: recent advances.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood obesity has become one of the most prevalent chronic health conditions and represents a major risk to normal growth and development in pediatric populations. As its global incidence continues to rise, increasing attention has been directed toward sarcopenic obesity (SO) as an important and emerging phenotype. This condition is defined by the coexistence of excessive adiposity and diminished muscle mass, which can negatively influence physical development as well as skeletal health in children. During childhood and adolescence, skeletal growth progresses rapidly and is highly sensitive to metabolic and hormonal influences. In this context, SO may impair bone formation via mechanical loading alterations, endocrine dysregulation, and chronic low-grade inflammation, ultimately contributing to reduced bone mineral content. Moreover, the combined impact of excess fat and insufficient muscle mass during these critical developmental stages may have long-term consequences that extend into adulthood, highlighting the importance of timely prevention and intervention. This narrative review examines the relationship between sarcopenic obesity and bone mass in children. It synthesizes recent evidence on epidemiology, underlying pathophysiological mechanisms, clinical features and evidence, as well as screening and management strategies, and further proposes recommendations focused on lifestyle-based interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.